The CR technique was used for the first time to determine the important role of the MYC-ERCC3 interaction in pancreatic ductal adenocarcinoma (PDAC), and triptolide (a covalent ERCC3 inhibitor) was found to be a potential treatment target in MYC-dependent PDAC (Beglyarova et al., 2016). This evidence concerns the gene MYC and pancreatic ductal adenocarcinoma.